Modality
Multispecific
MOA
Cl18.2
Target
TIGIT
Pathway
Cell Cycle
MesoEpilepsy
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
~Nov 2020
→ ~Feb 2022
Phase 3
~May 2022
→ ~Aug 2023
NDA/BLA
~Nov 2023
→ ~Feb 2025
Approved
May 2025
ApprovedCurrent
NCT05413928
330 pts·Epilepsy
2025-05→TBD·Active
330 total pts1 indication
CompletedCurrentUpcoming
Trial Timeline
Approved
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05413928 | Approved | Epilepsy | Active | 330 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |